Which Peptides Can Legally Be Compounded?

Compounding is something a licensed pharmacy does — it is not something a supplier does. Under the federal framework, a peptide can generally be compounded only when a licensed 503A pharmacy or a registered 503B outsourcing facility can lawfully source it as an eligible bulk drug substance: broadly, the substance is a component of an FDA-approved drug, is the subject of an applicable USP or NF monograph, or appears on the FDA list of bulk drug substances permitted for use in compounding. A peptide that clears none of those doors is generally not eligible, no matter how often it appears in trade press. Research-use-only material — the category Real Peptides supplies through its Wholesale Partner Program — sits outside that pathway entirely and is never a compounding input.

This article is informational and is not legal advice. Compounding eligibility is a live regulatory question that shifts as agency lists are updated, and state boards of pharmacy layer their own requirements on top. Confirm anything below with your own attorney and your state board before you build a business decision on it.

The three doors a substance has to pass through

The statutory architecture is easier to hold in your head than most people expect. Federal law carves out an exemption from the usual new-drug approval requirements for compounded preparations, but that exemption is conditional. One of those conditions concerns the bulk drug substance itself.

In general terms, a bulk substance used in compounding must satisfy one of three conditions: it is a component of a drug approved by FDA; it is the subject of an applicable monograph in the United States Pharmacopeia or the National Formulary; or it appears on the agency's list of bulk drug substances that may be used in compounding. There are additional conditions around sourcing — the substance generally must be accompanied by a valid certificate of analysis and obtained from a registered facility.

That structure is why the question is never really "is this peptide legal?" The question is narrower and more useful: which of the three doors does this specific substance walk through, and can the pharmacy document it. Plenty of peptide sequences with substantial published research behind them walk through none of them. Research interest and regulatory eligibility are separate axes, and confusing the two is the single most common error a business buyer makes when evaluating this space.

Why the eligible list is a moving target

FDA evaluates substances that have been nominated for the compounding bulks list and sorts its findings into categories — broadly, substances it may consider for the list, substances it has identified as raising significant safety risk, and substances that were nominated without enough supporting information to evaluate. Those determinations get published, and they change.

This matters more for peptides than for most drug classes. Over the past several years the agency has published evaluations covering a number of peptide substances, and several compounds that had circulated widely in the compounding channel were placed in the category flagged for significant safety risk. Others were never nominated with sufficient information to be evaluated at all. As of 2026, the practical instruction for a buyer is simple: treat the list as a live document, pull the current published version directly from the agency before assuming any specific substance is eligible, and do not rely on a supplier's summary of what the list says.

If a vendor tells you a particular peptide is "compoundable" without pointing you to the current published determination, that is not a sourcing answer — it is a sales answer. Ask which door the substance walks through and ask for the document.

The size threshold that reclassifies everything

There is a second gate most buyers have never encountered. Federal law defines biological products in a way that turns on molecular size, and peptides above a certain amino acid count fall on the biologic side of that line rather than the small-molecule drug side. Products regulated as biologics are licensed under a different statutory pathway, and the compounding exemptions that apply to drugs do not map cleanly onto them.

The practical consequence is that a sequence's length can determine which regulatory regime governs it before anyone gets to the question of monographs or bulks lists. Longer peptides and peptide-adjacent proteins may sit in the biologics regime entirely. Shorter sequences remain in the drug regime, where the three-door analysis applies.

You do not need to become a regulatory specialist to use this. You need to know the gate exists, so that when someone tells you a longer sequence is "just a peptide" and therefore compoundable, you recognize that as an unexamined claim rather than a settled fact.

Two facility types, two very different rulebooks

Buyers often use "compounding pharmacy" as a single category. Federally, there are two, and the distinction changes what can be produced, in what quantity, and under what oversight.

The two bulks lists are not interchangeable. A substance's status under one framework tells you very little about its status under the other. If your business model depends on sourcing from either type of facility, that verification belongs to your counsel and to the facility itself — not to a supplier catalog.

The questions to take to your attorney and your state board

Rather than looking for a jurisdiction that "allows" something, bring specific questions to people who can answer them on the record for your situation:

What licensure does my business hold, and what does it actually authorize me to purchase, hold, and transfer? Does my state board draw a distinction between purchasing research-use-only material and purchasing drug products, and how is that distinction documented in an inspection? If I resell, what registrations or permits attach to that activity in every state I ship into? What labeling and recordkeeping obligations follow the material once it is in my possession? Where does my professional liability coverage end?

A few notes on scope. If any part of your research work touches veterinary contexts, talk to a licensed veterinarian — animal drug compounding operates under its own guidance and its own set of conditions, and assuming the human framework transfers is a mistake. And if a supplier volunteers confident legal conclusions about what your state permits, treat that as a red flag rather than a service. Suppliers are not your counsel, and no reputable one pretends otherwise.

Research-use-only material is a separate supply chain

Here is the distinction that resolves most of the confusion in this category. Compounded preparations are drug products, made by licensed facilities, intended for administration. Research-use-only compounds are laboratory materials, sold for in-vitro and non-clinical research, not intended or approved for human consumption. They are not compounding inputs, they are not drugs, and they are not substitutes for either.

Real Peptides operates in the second lane. Every compound in the catalog — from widely studied sequences like BPC-157 and GHK-Cu through the broader popular peptides collection — is supplied strictly for research purposes. Where published work exists on these sequences, research suggests mechanisms worth studying; that is a statement about the literature, not a claim about outcomes in people.

For a wholesale buyer, the clean version of the business question is: am I stocking research materials for a research audience, with accurate labeling and honest framing, or am I trying to occupy a pharmacy's role without a pharmacy's license? The first is a defensible catalog decision. The second is a conversation to have with your attorney before you place an order anywhere.

What to verify before you stock any supplier

The diligence that matters is narrow and repeatable. Ask for a certificate of analysis tied to the specific lot you would receive, and check whether you can view results without a purchase — some sellers gate COAs behind an order, or sell them separately, which tells you something. Ask what the analytical panel actually covers beyond a purity number: identity confirmation, and screening for the contaminants that matter in peptide manufacture, are the parts a single HPLC figure does not address on its own.

Ask where fulfillment happens and how long transit takes, because a stated lead time you cannot verify is a planning risk. Ask whether wholesale pricing is published or quoted case by case, and whether tier thresholds are disclosed up front. Hidden pricing is not always predatory, but it does make comparison shopping impossible, which is usually the point. Margins in this category vary widely with volume, category, and how you position your catalog — anyone quoting you a specific margin figure before seeing your business is guessing.

What Real Peptides does differently

Real Peptides supplies research compounds at 99%+ HPLC purity, with 7-panel batch testing applied to production lots. Certificates of analysis are publicly verifiable — a prospective partner can check the lab results directly rather than requesting them through a sales representative or paying for access. Fulfillment is US-based, with orders shipping in five to seven days.

Wholesale access runs through a three-step application. Businesses submit their details, the account is reviewed, and approved partners receive tier pricing and ordering access. The catalog spans the categories most partner businesses stock, and product pages carry the research-use-only framing consistently, which matters if your own labeling and marketing need to stay aligned with how the material was sold to you.

If your business is stocking research compounds

If you have confirmed with your counsel that carrying research-use-only material fits your licensure and your model, the next step is the wholesale peptides program, where tiers and the qualification criteria are laid out. Qualified businesses can apply for a wholesale account and review published COAs before committing to a first order.